There's an arms race in medicine -- scientists design drugs to treat lethal bacterial infections, but bacteria can evolve defenses to those drugs, sending the researchers back to square one. A team ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug ...

Summit Therapeutics (SMMT) enters a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (PFE) antibody drug conjugates across multiple solid tumor ...

As OS Therapies prepares to take its bacteria-based lung cancer therapy to the FDA for approval, the biotech has been ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.